Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma

American Journal of Hematology

Volumn 81, Issue 5, 2006, Pages 307-314

  Eser, Bulent ^a,c   Sari, Ismail ^a   Canoz, Ozlem ^a   Altuntas, Fevzi ^a   Cakmak, Erol ^a   Ozturk, Ahmet ^b   Ozkan, Metin ^a   Er, Ozlem ^a   Cetin, Mustafa ^a   Unal, Ali ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Apoptosis; Fas; Non Hodgkin's lymphoma; Prognosis and therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FAS ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

ADULT; AGE; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DRUG RESPONSE; ECOG PERFORMANCE STATUS; FEMALE; FUNCTIONAL STATUS; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIMARY NODAL DIFFUSE LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STATISTICAL ANALYSIS; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS;

EID: 33646478877     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20564     Document Type: Article

References (37)

1. Harris NL, Jaffe ES, Stein H, Banks PM, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Offit K, Lo Coco F, Louie DC, Parsa NZ, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994;331:74-80.
3. The International non-Hodgkin's Lymphoma Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
4. Kramer MH, Hermans J, Parker J, Krol AD, et al. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-2138.
5. Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994;69:337-341.
6. Jackel MC, Mitteldorf C, Schweyer S, Füzesi L. Clinical relevance of FAS (Apo-1/CD95) expression in laryngeal squamous cell carcinoma. Head Neck 2001;23:646-652.
7. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000;89:127-132.
8. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999;84:239-243.
9. Shibakita M, Tachibana M, Dhar DK, Kotoh T, et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999;5:2464-2469.
10. Nguyen PL, Harris NL, Ritz J, Robertson MJ. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996;148:847-853.
11. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000;143:313-319.
12. Zoi-Toli O, Meijer CJ, Oudejans JJ, de Vries E, van Beek P, Willemze R. Expression of Fas and Fas ligand in cutaneous B-cell lymphomas. J Pathol 1999;189:533-538.
13. Kondo E, Yoshino T, Yamadori I, Matsuo Y, et al. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 1994;145:330-337.
14. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging. Cancer Res 1971;31:1860-1861.
15. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
16. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 2001;19:129-150.
17. van Haselen CW, Toonstra J, van der Putte SJ, van Dongen JJ, van Hees CL, van Vloten WA. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. J Cutan Pathol 1997;24:462-467.
18. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
19. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288:2351-2354.
20. Fraser A, Evan G. A license to kill. Cell 1996;85:781-784.
21. Strasser A, Newton K. FADD/MORT1, a signal transducer that can promote cell death or cell growth. Int J Biochem Cell Biol 1999;31:533-537.
22. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998;94:695-698.
23. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296:1635-1636.
24. Nagata S. Fas-induced apoptosis. Intern Med 1998;37:179-181.
25. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo. Dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87:319-329.
26. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 1995;17:51-61.
27. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-1456.
28. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-574.
29. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995;166:236-246.
30. El-Khatib M, Stanger BZ, Dogan H, Cui H, Ju S-T. The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones. Cell Immunol 1995;163:237-244.
31. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439-459.
32. Aftabuddin M, Yamadori I, Yoshino T, Kondo E, Akagi T. Correlation between the number of apoptotic cells and expression of the apoptosis-related antigens Fas, Le(y) and bcl-2 protein in non-Hodgkin's lymphomas. Pathol Int 1995;45:422-429.
33. Rijlaarsdam JU, van der Putte SC, Berti E, Kerl H, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993;23:117-125.
34. Takakuwa T, Dong Z, Nakatsuka S, Kojya S, et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 2002;21:4702-4705.
35. Maeda T, Yamada Y, Moriuchi R, Sugahara K, et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999;189:1063-1071.
36. Ng CS, Lo ST, Chan JK. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. Hum Pathol 1999;30:48-53.
37. Landowski TH, Moscinski L, Burke R, Buyuksal I, et al. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma 2001;42:835-846.